Abstract
Electroencephalography and Magnetoencephalography have provided valuable information about the brain functioning in psychosis. In the last few years, authors have demonstrated that there are neurophysiological alterations already in the prodromal period, before the development of psychosis. This makes them promising tools for predicting a future transition to psychosis. In this paper we review the latest studies using event-related potentials (ERP) in subjects clinically at high-risk of developing psychosis. We particularly focus in the P300, Mismatch-Negativity (MMN) and P50 paradigms, discussing the main findings, but also the limitations and challenges in electrophysiological studies in this population.
Keywords: Prodrome, psychosis, EEG, ERP, Magnetoencephalography, pre-psychotic phase, schizophrenia, healthy controls, Mismatch negativity (MMN), Comprehensive Assessment of At-Risk Mental States (CAARMS)
Current Pharmaceutical Design
Title: Neurophysiological Alterations in the Prepsychotic Phases
Volume: 18 Issue: 4
Author(s): Nicolas A. Crossley, Miguel Constante, Paolo Fusar-Poli and Elvira Bramon
Affiliation:
Keywords: Prodrome, psychosis, EEG, ERP, Magnetoencephalography, pre-psychotic phase, schizophrenia, healthy controls, Mismatch negativity (MMN), Comprehensive Assessment of At-Risk Mental States (CAARMS)
Abstract: Electroencephalography and Magnetoencephalography have provided valuable information about the brain functioning in psychosis. In the last few years, authors have demonstrated that there are neurophysiological alterations already in the prodromal period, before the development of psychosis. This makes them promising tools for predicting a future transition to psychosis. In this paper we review the latest studies using event-related potentials (ERP) in subjects clinically at high-risk of developing psychosis. We particularly focus in the P300, Mismatch-Negativity (MMN) and P50 paradigms, discussing the main findings, but also the limitations and challenges in electrophysiological studies in this population.
Export Options
About this article
Cite this article as:
A. Crossley Nicolas, Constante Miguel, Fusar-Poli Paolo and Bramon Elvira, Neurophysiological Alterations in the Prepsychotic Phases, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316307
DOI https://dx.doi.org/10.2174/138161212799316307 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design The Role of Inflammation in Epilepsy
Current Pediatric Reviews Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Neurotransmitter Regulation of Adult Neurogenesis: Putative Therapeutic Targets
CNS & Neurological Disorders - Drug Targets The Neuropharmacological Preclinical Effects of <i>Nigella sativa</i>: A Review
Current Bioactive Compounds On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry Pycnogenol Protects against Pentylenetetrazole-Induced Oxidative Stress and Seizures in Mice
Current Clinical Pharmacology Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral Studies
Current Neuropharmacology Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Shining Light on an mGlu5 Photoswitchable NAM: A Theoretical Perspective
Current Neuropharmacology Editorial [Hot topic: An Overview on the Design, Development, Characterization and Applications of Novel Nanomedicines for Brain Targeting (Guest Editor: Eliana B. Souto)]
Current Nanoscience Transient Receptor Potential Vanilloid 1 and Xenobiotics
CNS & Neurological Disorders - Drug Targets Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence
CNS & Neurological Disorders - Drug Targets Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry